Open AccessGLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis
Author(s) -
Satoshi Kurita,
Justin L. Mott,
Luciana L. Almada,
Steven F. Bronk,
Nathan W. Werneburg,
ShiYong Sun,
Lewis R. Roberts,
Martín E. Fernández-Zapico,
Gregory J. Gores
Publication year - 2010
Publication title -
oncogene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.395
H-Index - 342
eISSN - 1476-5594
pISSN - 0950-9232
DOI - 10.1038/onc.2010.235
Subject(s) - biology , gene knockdown , gli1 , hedgehog , cancer research , transcription factor , hedgehog signaling pathway , cyclopamine , small interfering rna , gli3 , apoptosis , cytotoxicity , microbiology and biotechnology , effector , chromatin immunoprecipitation , downregulation and upregulation , gli2 , signal transduction , gene expression , cell culture , transfection , biochemistry , promoter , repressor , genetics , gene , in vitro
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis through its cognate receptors death receptor 4 (DR4) and death receptor 5 (DR5), preferentially in malignant cells. However, many malignant cells remain resistant to TRAIL cytotoxicity by poorly characterized mechanisms. Here, using cholangiocarcinoma cells, as a model for TRAIL resistance, we identified a role for the oncogenic Hedgehog (Hh)-GLI pathway in the regulation of TRAIL cytotoxicity. Blockade of Hh using pharmacological and genetic tools sensitizes the cells to TRAIL cytotoxicity. Restoration of apoptosis sensitivity coincided with upregulation of DR4 expression, while expression of other death effector proteins remained unaltered. Knockdown of DR4 mimics Hh-mediated resistance to TRAIL cytotoxicity. Hh regulates the expression of DR4 by modulating the activity of its promoter. Luciferase, chromatin immunoprecipitation and expression assays show that the transcription factor GLI3 binds to the DR4 promoter and Hh requires an intact GLI3-repression activity to silence DR4 expression. Finally, small interfering RNA (siRNA)-targeted knockdown of GLI3, but not GLI1 or GLI2, restores DR4 expression and TRAIL sensitivity, indicating that the Hh effect is exclusively mediated by this transcription factor. In conclusion, these data provide evidence of a regulatory mechanism, which modulates TRAIL signaling in cancer cells and suggest new therapeutic approaches for TRAIL-resistant neoplasms.